Heron Therapeutics | HRTX - Cost Of Sales


Heron Therapeutics reported $11.12M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Eisai JPY 52.02B 931M Mar/2026
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 50.74M 3.89M Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Veracyte USD 38.49M 794K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026